Results 41 to 50 of about 12,281 (206)

Primary autoimmune myelofibrosis: A case report in a child

eJHaem, 2020
Autoimmune myelofibrosis (AIMF) is an uncommon cause of myelofibrosis associated with favorable outcome. Primary AIMF, AIMF without a known systemic autoimmune disorder, has been described in adults, but never in children. Here, we present, for the first
Zufit Hexner‐Erlichman, Joanne Yacobovich, Philippe Trougouboff, Moran Avraham‐Kelbert, Harel Eitam, Ronen Spiegel, Shay Yeganeh, Carina Levin   +7 more
doaj   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

Haematologica, 2011
Risk stratification in primary myelofibrosis is currently based on two international prognostic scoring systems, neither of which takes into consideration red blood cell transfusion-dependency.
Chiara Elena, Francesco Passamonti, Elisa Rumi, Luca Malcovati, Luca Arcaini, Emanuela Boveri, Michele Merli, Daniela Pietra, Cristiana Pascutto, Mario Lazzarino   +9 more
doaj   +1 more source

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M, Fleischman, Angela G, Huynh, Christy, Morse, Sarah J, Nguyen, Hellen, Nguyen, Jenny, Nguyen, Thanh Kim   +6 more
core  

Recent advances in therapies for primary myelofibrosis

Faculty Reviews, 2023
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling. PMF as well as secondary MF (post-ET and post-PV MF) are the most aggressive MPNs.
Vainchenker, W, Yahmi, N, Havelange, V, Marty, C, Plo, I, Constantinescu, SN   +5 more
openaire   +3 more sources

Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]

, 2016
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core   +2 more sources

ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS

Acta Biomedica Scientifica, 2017
Ph-negative myeloproliferative neoplasm are the group of hematologic disorders which includes primary myelofibrosis, polycythemia vera, essential trombocytemia and several rare diseases.
A. N. Alekseeva, O. E. Ochirova, L. B. Sodnomova, E. B. Zhalsanova   +3 more
doaj   +1 more source

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase

Haematologica, 2014
Myelofibrosis is a myeloproliferative neoplasm that occurs de novo (primary myelofibrosis) or results from the progression of polycythemia vera or essential thrombocytemia (hereafter designated as secondary myelofibrosis or post-polycythemia vera ...
Mandy Brecqueville, Jérôme Rey, Raynier Devillier, Arnaud Guille, Rémi Gillet, José Adélaide, Véronique Gelsi-Boyer, Christine Arnoulet, Max Chaffanet, Marie-Joelle Mozziconacci, Norbert Vey, Daniel Birnbaum, Anne Murati   +12 more
doaj   +1 more source

The diagnosis and management of the haematologic manifestations of lupus [PDF]

, 2016
Haematological manifestations in systemic lupus erythematosus (SLE) are frequently observed. They are diverse and range from mild to severe.
Castro, SG, Isenberg, DA, Velo-García, A   +2 more
core   +1 more source

TP53 mutations and Polymorphisms in Primary Myelofibrosis, [PDF]

Blood, 2011
Abstract Abstract 3840 Background: Patients with myeloproliferative neoplasms (MPN) harbor a multitude of somatic mutations involving JAK2, MPL, LNK, CBL, TET2, ASXL1, IDH1, IDH2, EZH2, DNMT3A, IKZF1 and TP53.
Rhett P. Ketterling, Animesh Pardanani, Ryan A. Knudson, Lori A. Erickson, Christy Finke, David S. Viswanatha, Terra L. Lasho, Ayalew Tefferi, Sania S Raza   +8 more
openaire   +4 more sources